MSD's Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension (PAH) achieved its primary endpoint, showing efficacy in high-risk patients. The study recommended early termination based on positive results. WINREVAIR's potential was highlighted for future PAH treatments.